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Cancer cells in culture obtain ATP and biosynthetic precursors primarily by aerobic glycolysis, not by
mitochondrial glucose oxidation. In this issue of Cell Metabolism, Marin-Valencia et al. (2012) demonstrate
that glioblastoma, an aggressive and, in culture, highly glycolytic cancer, primarily uses glucose oxidation
to meet energetic and biosynthetic demands in vivo.Cancer cells preferentially metabolize
glucose to lactate, despite sufficient levels
of oxygen to support mitochondrial glu-
cose oxidation (i.e., The Warburg effect).
This provides less ATP per molecule of
glucose, but cancer cells derive signifi-
cant gain from the metabolic shortcut.
Aerobic glycolysis yields enough ATP to
meet energetic demand while providing
NADPH and nutrient precursors for lipid
biogenesis and macromolecular syn-
thesis (Vander Heiden et al., 2009). It has
been inferred that human cancers in vivo
also rely primarily on aerobic glycolysis,
but do they? Unlike established cell-line
models that have been used to provide
insight into cancer metabolic reprogram-
ming, human tumors in situ present a
much more complex and heterogeneous
microenvironment. A more complete un-
derstanding of the metabolic behavior
of human tumors requires models that
more accurately reflect this complexity.
Marin-Valencia et al. (2012) performmeta-
bolic flux analysis of 13C-labeled nutrients
in human orthotopic tumor models
(HOTs), inwhich cells isolated fromclinical
tumor samples are implanted directly into
the brain ofmice. Theyprovide compelling
evidence to suggest that glioblastomas
utilize mitochondrial glucose oxidation
in vivo to support aggressive tumor
growth (Figure 1).
Aerobic glycolysis is not exclusive to
cancer. Proliferative normal cells can
also use thismechanism, butwith a salient
difference. Aerobic glycolysis in non-
neoplastic cells remains responsive to
environmental levels of nutrients and
growth factors, a process that is orches-
trated through tightly regulated feed-
forward and feedback signaling loops(Koppenol et al., 2011). In contrast,
cancer cells appear to be ‘‘addicted’’
to aerobic glycolysis because their re-
gulatory circuits are overwhelmed by
persistent oncogenic driver mutations.
This difference could potentially be thera-
peutically exploited. The use of dichlor-
oacetate (DCA), a pharmacological inhib-
itor of pyruvate dehydrogenase kinase
(PDK), to target glioblastoma, a highly
glycolytic, highly aggressive form of pri-
mary brain cancer, provides one example
(Michelakis et al., 2010). Suppression of
PDK by DCA derepresses the pyruvate
dehydrogenase complex (PDH), enabling
flux through the citric acid cycle. This
targeting strategy assumes that glioblas-
tomas rely almost exclusively on aerobic
glycolysis and that forcing tumor cells
to use mitochondrial glucose oxida-
tion could be a lethal insult. There is
some empirical evidence to support this
hypothesis (Michelakis et al., 2010). How-
ever, a recent study of brain tumors from
patients infused with 13C -labeled glucose
does not support the underlying hypoth-
esis, instead demonstrating extensive
glucose mitochondrial oxidation (Maher
et al., 2012).
Now, Marin-Valencia et al. (2012)
present a rigorous analysis of the meta-
bolic fate of labeled nutrients in glioblas-
tomas grown in their native microenvi-
ronment. They establish and genomically
characterize a set of HOT models derived
from tumor cells isolated during surgical
resection of human glioblastomas and
implanted directly into the brain of immu-
nodeficient mice. These models are never
placed in culture, preventing selection for
tumor cells best adapted to the artificial
environment of cell culture and maintain-Cell Metabolisming the heterogeneous microenvironment
of the native tumor. Following establish-
ment and molecular characterization to
ensure that the models are representative
of tumors from which they were derived,
Marin-Valencia et al. infused the mice
with 13C -labeled nutrients in which the
carbons are labeled at various positions.
By using 13C NMR spectroscopy of tumor
tissue and normal brain extracts, the fate
of the nutrients could by traced by analyz-
ing the position of the labeled carbons in
the metabolites—and by the spectra
themselves (singlets, doublets, and so
on). Regardless of genotype, all glioblas-
tomas characterized demonstrated gly-
colysis and mitochondrial glucose oxida-
tion via PDH and the citric-acid cycle.
Further, the analyses demonstrated that
glucose supplied the metabolic interme-
diates for a number of biosynthetic activ-
ities. The HOT models also contained
elevated levels of glutamine, but lacked
glutamine catabolism and were not
dependent on exogenous glutamine for
growth, a result that may potentially be
explained by de novo glutamine synthesis
(Marin-Valencia et al., 2012).
This study raises a number of intriguing
questions. Cancer cells demonstrate a
striking ability to rewire their circuitry to
maintain flux to critical downstream
signaling nodes (Cloughesy and Mischel,
2011). Does the metabolic circuitry of
cancer show similar plasticity? Can tumor
cells utilize either mitochondrial glucose
oxidation or aerobic glycolysis if one or
the other route is blocked? It has already
been demonstrated that cancer cells that
are prevented from using glucose-derived
carbons for lipogenesis, due to either
genetic or pharmacologic perturbations15, June 6, 2012 ª2012 Elsevier Inc. 789
Figure 1. Glioblastomas in Their Native Microenvironment Primarily
Use Mitochondrial Glucose Oxidation to Meet Energetic and
Biosynthetic Demands
(A) When cells from a patient’s brain tumor are grown in culture, glucose is
primarily metabolized to lactate with minimal mitochondrial oxidation.
(B) Here, Marin-Valencia et al. show that when cells from a patient’s brain
tumor are implanted into the brain of immunodeficient mice to simulate
their native microenvironment, glioblastomas primarily utilize mitochondrial
glucose oxidation.
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through the citric-acid cycle,
can use glutamine as a source
for lipogenesis by reduc-
tive carboxylation with isoci-
trate dehydrogenase 1 (IDH1)
(Metallo et al., 2012; Mullen
et al., 2012). Metabolic flux
analysis of HOT models pro-
vides a promising experi-
mental platform for dissecting
the plasticity of cancer met-
abolic reprogramming, an
issue that may prove to be
critical for preventing or re-
versing resistance to meta-
bolically targeted therapies.
A second major theme re-
lates to the heterogeneity of
the microenvironment. Solid
organ cancers, including glio-
blastoma, are heteroge-
neous; individual tumor cells
may differ in functional and/
ormolecular attributes (Guptaet al., 2011). These cells are also influ-
enced by their location within the tumor,
i.e., near to or distant from a blood vessel,
and by neighboring cells through the local
chemical milieu. The hypoxic response
provides a possible example. Surpris-
ingly, few of the HOTs showed evidence
for robust HIFa expression on western
blot. However, it is highly likely that
subsets of tumor cells, particularly those
near necrotic regionsor distant fromblood
vessels may experience HIFa-dependent
metabolic reprogramming and thus may
differ in how they metabolize glucose
and glutamine. The technology used, by
necessity, assumed that the tumor cells
are metabolically homogeneous. How-
ever, cell-to-cell differences in metabolic
circuitry could potentially influence clonal
selection, if it provides tumor cell sub-
sets with an adaptive advantage. Future
studies examining metabolic heteroge-
neity in these models may prove to be790 Cell Metabolism 15, June 6, 2012 ª2012of enormous value. A third interesting,
and potentially surprising, result is the
relative uniformity of the metabolic fate of
glucose in these HOT models that did
not appear to dependongenotype. Future
studies applying genetic and pharma-
cologic modulations of key signaling
networks in these HOT models may yield
important information as to how genetic
context can influence the way tumors
utilize their nutrients in the native tumor
microenvironment.
This intriguing paper by Marin-Valencia
et al. may have important implications for
the field of cancer metabolism—and may
provide a valuable blueprint for dissecting
the metabolic circuitry of cancer across
various tumor types. It suggests that dis-
section of the metabolic circuitry of
cancer may require analysis in models
that recapitulate the native tumor micro-
environment; a theme that should res-
onate with investigators interested inElsevier Inc.diverse cancer types. It also
demonstrates, not surpris-
ingly, that cancers can also
use mitochondrial glucose
oxidation, particularly in
models systems simulating
their nativemicroenvironment
in vivo. Future studies will be
needed to better understand
how cancer cells balance
aerobic glycolysis with mito-
chondrial glucose oxidation
and whether either, or both,
are required to meet the
metabolic demands imposed
by aggressive tumor growth.REFERENCES
Cloughesy, T.F., and Mischel, P.S.
(2011). Clin. Cancer Res. 17, 6–11.
Gupta, P.B., Fillmore, C.M., Jiang,
G., Shapira, S.D., Tao, K., Kuper-
wasser, C., and Lander, E.S.
(2011). Cell 146, 633–644.
.H., Bounds, P.L., and Dang, C.V.Koppenol, W
(2011). Nat. Rev. Cancer 11, 325–337.
Maher, E.A., Marin-Valencia, I., Bachoo, R.M.,
Mashimo, T., Raisanen, J., Hatanpaa, K.J., Jindal,
A., Jeffrey, F.M., Choi, C., Madden, C., et al. (2012).
NMR Biomed. 2012, 15.
Marin-Valencia, I., Yang, C., Mashimo, T., Cho, S.,
Baek, H., Yang, X.L., Rajagopalan, K.N., Maddie,
M., Vemireddy, V., et al. (2012). Cell Metab. 15,
this issue, 827–837.
Metallo, C.M., Gameiro, P.A., Bell, E.L., Mattaini,
K.R., Yang, J., Hiller, K., Jewell, C.M., Johnson,
Z.R., Irvine, D.J., Guarente, L., et al. (2012). Nature
481, 380–384.
Mullen, A.R., Wheaton, W.W., Jin, E.S., Chen, P.H.,
Sullivan, L.B., Cheng, T., Yang, Y., Linehan, W.M.,
Chandel, N.S., and DeBerardinis, R.J. (2012).
Nature 481, 385–388.
Michelakis, E.D., Sutendra, G., Dromparis, P.,
Webster, L., Haromy, A., Niven, E., Maguire, C.,
Gammer, T.L., Mackey, J.R., Fulton, D., et al.
(2010). Sci. Transl. Med. 2, 31ra34.
Vander Heiden, M.G., Cantley, L.C., and
Thompson, C.B. (2009). Science 324, 1029–1033.
